New weekly shot could fight deadly mould infections with fewer side effects

NCT ID NCT07215273

Recruiting now Disease control Sponsor: Elion Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 7 times

Summary

This Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL219 once a week or standard antifungals (liposomal amphotericin B or voriconazole). The study measures survival at 21 days and tracks side effects, aiming to see if EL219 can offer a simpler and less toxic alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EL219 (Turletricin)
What this could lead to: If successful, this could provide a safer, once-weekly antifungal option for people with weakened immune systems who are at risk of serious mould infections.
What could go wrong: This is a small Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug could still cause side effects or fail to work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE MOULD INFECTION SUSPECTED INVASIVE MOULD INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

AP-HP Hopital Henri Modor
RECRUITING

Créteil, 94000, France
AZ Sint-Jan Brugge
RECRUITING

Bruges, 8000, Belgium
Augusta University Medical Center
RECRUITING

Augusta, Georgia, 30912, United States
Centre Hospitalier d'Argenteuil
RECRUITING

Argenteuil, 95107, France
Fondazione Policlinico Universitario A. Gemelli IRCCS- Universita Cattolica del Sacro Cuore
RECRUITING

Roma, 00168, Italy
Hospital Clinic Barcelona
RECRUITING

Barcelona, 08036, Spain
Hospital Clinico Universitario de Salamanca
RECRUITING

Salamanca, 37007, Spain
Hospital Universitario Puerta de Hierro
RECRUITING

Majadahonda, 28222, Spain
Hospital Universitario Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital del Mar
RECRUITING

Barcelona, 08024, Spain
Istituto Europeo di Oncologia
RECRUITING

Milan, 20141, Italy
Juravinski Hospital
RECRUITING

Hamilton, Ontario, L8V 1C3, Canada
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
U. of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
U. of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
U. of Texas, MD Anderson
RECRUITING

Houston, Texas, 77030, United States
UC Davis Medical Center
RECRUITING

Sacramento, California, 95817, United States
UZ Leuven
RECRUITING

Leuven, 3000, Belgium
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet
RECRUITING

Brussels, 1070, Belgium
Washington U.
RECRUITING

St Louis, Missouri, 63110, United States